Relcon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Relcon

Property Description
Active ingredient Tranexamic Acid
Form Tablet, Solution for Injection, Capsule
Pharmacological class Antifibrinolytic Agent
Common use Hemostasis (control of bleeding)
Origin Synthetic, Lysine Analog

The Core Identity: What Kind of Medicine is Relcon?

Relcon is a medicinal product whose therapeutic function is based on the active ingredient Tranexamic Acid, which is designed to specifically assist the body in managing blood loss. The substance is chemically classified as a synthetic small molecule, derived as an analog of the essential amino acid lysine. As a single-ingredient product, its effect is derived exclusively from this one pharmacological substance, concentrating its intended antihemorrhagic action. This focused composition allows for a predictable pharmacological effect, which is clinically recognized for its clot-stabilizing properties.

Pharmacological Class and General Purpose

Relcon belongs to the pharmacological class of antifibrinolytic agents, which is distinct from agents that directly promote clotting. Its classification highlights a specialized role: it acts by interrupting the body's natural process of fibrinolysis, the enzymatic breakdown of blood clots. This class provides critical support for clot integrity in bleeding conditions, assisting the body in maintaining strong, functional blood clots. The core purpose of Relcon is to provide potent support in controlling excessive bleeding by reinforcing the clot structure and preventing its premature dissolution.

Available Preparations and Routes

Tranexamic Acid is widely formulated into several pharmaceutical preparations to suit varied medical needs. These dosage forms include tablets for oral use and a sterile solution for injection intended for intravenous administration. This duality of forms is essential because it allows the medicine to be delivered either systemically via injection for rapid control in acute settings or orally for less immediate requirements, ensuring the therapeutic effect is delivered precisely according to the required site of action.

What side effects are possible with Relcon?

Relcon's safety profile, based on its classification as an antifibrinolytic agent, is documented by government regulatory authorities through classifications of adverse reactions and specific safety constraints.

Officially Documented Adverse Reactions by Frequency

Side effects are officially classified by the estimated frequency of occurrence:

  • Common (1/100 to <1/10): Primarily gastrointestinal disorders, including nausea, vomiting, diarrhoea, and abdominal discomfort.
  • Uncommon (1/1,000 to <1/100): Allergic skin reactions (dermatitis allergic).
  • Frequency Not Known: This classification applies to several serious effects, including convulsions (seizures), arterial or venous thrombosis at any site, and severe hypersensitivity reactions such as anaphylaxis.

System-Organ-Class Safety Groups

The regulatory documents map potential effects to physiological systems, including the Gastrointestinal system, Vascular system, Nervous system, and Eye disorders (such as visual disturbances and impaired colour vision).

Serious Safety Constraints

The most serious safety considerations are centred on the risk of thromboembolic events, which are a primary constraint of the medicine. The medicine is also subject to critical restrictions for administration; for instance, the use of the injectable form in the neuraxial space (e.g., intrathecal or epidural) is strictly contraindicated due to the risk of severe neurological injury and fatal events.

Population-Specific Considerations

Official labeling defines specific safety requirements for certain populations. The medicine is contraindicated in severe renal impairment due to the risk of drug accumulation and is generally not recommended during the first trimester of pregnancy. Furthermore, high intravenous doses are associated with an increased frequency of convulsions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Relcon (Tranexamic Acid) is formally documented in government regulatory materials with a specific profile of clinical signs and potential severe outcomes. Documented manifestations, which may present after excessive exposure, include neurological effects such as convulsions (seizures), myoclonus (uncontrolled twitching), headache, and mental status changes. Gastrointestinal signs like severe nausea, vomiting, and diarrhea are also listed, along with visual impairment and chromatopsia.

Regulatory documents highlight the potential for life-threatening complications, including thromboembolic events (such as deep vein thrombosis or cerebral thrombosis) and the risk of acute renal cortical necrosis. Due to this documented severity, official guidance mandates that immediate medical attention must be sought if a seizure, collapse, or signs of a severe blood clot develop. Management is defined as strictly symptomatic and supportive, as no specific antidote is known for this overdose.

A specific population-based note is the requirement for mandatory dose reduction in patients with impaired kidney function, which is necessary to prevent accumulation that could lead to toxicity. Furthermore, the labeling notes that accidental neuraxial injection is an administration route error associated with severe, dose-independent overdose effects.

Therapeutic Uses of Relcon

What Relcon Treats: Main Uses and Benefits

Relcon is commonly used in clinical settings that involve acute or unstable symptom patterns related to significant blood loss. It is generally applied across domains where additional symptomatic support is needed to control bleeding.

The medication may be part of symptomatic management for conditions presenting with disruptive manifestations, specifically: excessive uterine bleeding (menorrhagia), bleeding during high-risk dental procedures, severe trauma, and certain inherited disorders like hereditary angioedema. The primary patient benefit is providing support that helps ease the overall symptom burden by assisting with the control of blood loss during a time of heightened physiological activity.

“Relcon is considered relevant for easing symptoms related to pronounced mucosal bleeding and for managing severe hemorrhage in acute contexts.”

For those experiencing recurrent or episodic manifestations of heavy bleeding, Relcon helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Managing Symptoms of Excessive Bleeding

Quick Fact: Managing Symptoms of Excessive Bleeding Relcon may assist with supporting patients during episodes of acute or recurrent excessive bleeding.

Regulatory References

  1. NIH StatPearls overview of Tranexamic Acid

Eligibility and Restrictions for Use

Who Can and Cannot Use Relcon?

Eligibility for Relcon (Tranexamic Acid) is strictly determined by official regulatory documents, primarily focusing on minimizing the risk of adverse clotting events.

Populations Who Must Not Use Relcon (Contraindications)

The medicine is formally contraindicated and must not be used by specific patient groups, including:

  • Patients with active intravascular clotting (e.g., active thromboembolic disease).
  • Individuals with a history of thrombosis, including retinal vessel occlusion.
  • Patients with known hypersensitivity to the active ingredient.
  • Those with subarachnoid hemorrhage (for the injection form).
  • Women using combined hormonal contraceptives (for the oral form used for heavy menstrual bleeding).

Condition and Age-Related Restrictions

Population/Condition Eligibility Status (Regulatory Basis)
Severe Renal Impairment Contraindicated (due to accumulation risk)
Mild to Moderate Renal Impairment Conditional Use (requires careful consideration)
Pregnancy Not Recommended (particularly in first trimester, due to insufficient data)
Breastfeeding Not Recommended (drug is excreted in milk)
Children Intravenous form approved from one year of age; oral form use not established under age 12.
Hepatic Impairment Use is allowed (no official dosage adjustment needed)

Eligibility is defined by official labeling and is conditional on avoiding these specific risk factors and conditions.

What should I know about interactions with other medicines?

Relcon's interaction profile focuses primarily on the pharmacodynamic risk of increased clot formation rather than metabolic or transporter-based effects. A key restriction is the formal contraindication for co-administration of oral Relcon with Combined Hormonal Contraceptives in females of reproductive potential. This restriction is documented in regulatory labeling due to the risk of additive effects leading to venous and arterial thrombosis.

Official guidance further advises the avoidance of concomitant use with various pro-thrombotic medical products, including:

  • Factor IX Complex Concentrates
  • Anti-inhibitor Coagulant Concentrates

Use is also not recommended with All-Trans Retinoic Acid (Oral Tretinoin) during the remission induction phase for Acute Promyelocytic Leukemia, as this combination may exacerbate procoagulant effects.

Regarding how the body processes Relcon, no clinically significant interactions with the Cytochrome P450 enzyme system, drug transporters, food, alcohol, or herbal products are explicitly documented in major government labels. However, the regulatory profile officially notes that the drug’s clearance is significantly reduced by Impaired Renal Function. This condition results in altered plasma exposure and is an important pharmacokinetic consideration documented in official labeling.

Mechanism of Action

Molecular Stabilization of the Fibrin Clot

The primary action of Relcon is the competitive inhibition of the fibrinolytic system. The molecule, a structural analog, binds competitively to the Lysine Binding Sites (LBS) on the Plasminogen zymogen. This binding prevents plasminogen from anchoring onto the Fibrin meshwork of a developing clot, thereby suppressing its activation into the clot-degrading enzyme, Plasmin. This molecular interference leads to the physiological consequence of sustained resistance to fibrin degradation and preserved structural integrity of the fibrin matrix.

Off-Target Modulation of Central Inhibition

At plasma concentrations significantly higher than those required for its primary action, the drug engages a secondary, off-target mechanism by functioning as an antagonist at the inhibitory GABA A receptor in the central nervous system (CNS). This interaction modulates neuronal signaling by reducing the function of the brain's inhibitory pathways. This secondary mechanism leads to the physiological consequence of neuronal hyperexcitability, defining a concentration-dependent limitation of the mechanism.

Dosage and Administration Information

Official Administration Instructions for Relcon

Instructions for Use (IFU) documents for prescription medicines provide the definitive, step-by-step guidance on how a drug product must be prepared and administered by the patient or caregiver. This standardized information ensures the medicine is used according to the precise conditions under which it was tested and approved. The table below summarizes the core domains that define the correct official use protocol for Relcon.

Instruction Domain Guideline Overview
Route of Administration [PLACEHOLDER: Specifies the exact method of delivery, e.g., Oral, Subcutaneous, or Intravenous use.]
Dosing Schedule [PLACEHOLDER: Sets the approved quantity and interval, e.g., 20 mg once daily or 500 mg every 8 hours.]
Preparation Requirements [PLACEHOLDER: Details any necessary steps before use, e.g., Shake suspension for 10 seconds or Reconstitute powder with 5 mL of diluent.]
Missed Dose Rules [PLACEHOLDER: States the procedure for a forgotten dose, e.g., Take the missed dose immediately, unless it is within 4 hours of the next scheduled dose.]
Age-Group Rules [PLACEHOLDER: Defines any specific dose adjustments or administration methods for pediatric or geriatric patients.]

Official Procedural Structure

The full Instruction for Use document contains a detailed, action-oriented, step-by-step sequence that must be followed for safe and effective use.

Official step sequence:

  • Step 1: [PLACEHOLDER: e.g., Verify the expiration date on the Relcon container and ensure the integrity of the product.]
  • Step 2: [PLACEHOLDER: e.g., Perform any required preparation, such as shaking the bottle or reconstituting the powder.]
  • Step 3: [PLACEHOLDER: e.g., Measure the dose precisely using the calibrated device provided with the medicine.]
  • Step 4: [PLACEHOLDER: e.g., Administer the medicine at the specified time, such as taking the oral dose with or without food.]

Connection to the Overall Use Protocol

These instructions define the established protocol for the medicine. The strict adherence to the Route of Administration and Dosing Schedule ensures that the drug concentration in the body remains within the therapeutically approved range. The rules for Preparation Requirements and Missed Dose Rules provide the standardized actions necessary to maintain the integrity of the treatment course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Relcon (Tranexamic Acid)

Evidence for Use in Heavy Menstrual Bleeding (Menorrhagia)

Relcon was studied for women experiencing heavy menstrual bleeding, a condition characterized by fluctuating or episodic manifestations. The research base is primarily composed of Randomized Controlled Trials (RCTs) and systematic reviews. Studies typically included adult women who were not postmenopausal. Researchers designed trials to measure outcomes by quantifying the volume of blood loss per cycle and collecting patient-reported outcomes describing perceived discomfort and limitations in daily functioning.

Findings from these trials describe patterns observed in the studies that measured changes in blood loss volume. Research highlights changes measured during the study period, including patterns of change in patient-reported outcomes describing perceived discomfort and activity level. What is still uncertain in this area is the limited information for long-term outcomes when the medicine was observed in trials for extended durations beyond six months.

Evidence for Use in Severe Acute Hemorrhage

The evidence for Relcon research has explored the use of severe, acute blood loss from conditions like trauma and postpartum hemorrhage (PPH), based on very large, international Randomized Controlled Trials and meta-analyses. Key measurements observed included overall mortality (risk of death) at specific time points (e.g., 28 days) and the requirement for blood transfusions. Research examined measurements related to all-cause mortality that were associated with rapid administration following traumatic injury.

However, the observed pattern appears to be highly time-dependent. Data also show patterns where findings were mixed or inconsistent when exploring its use for specific injury subsets, such as patients with isolated traumatic brain injury.

Evidence in Special Populations and Uncertainties

Specific research was studied for certain age groups, such as adolescents experiencing heavy menstrual bleeding, and for patients with a bleeding disorder during procedures like tooth extractions. However, data for certain groups, such as the older adult population and women who are breastfeeding, remain insufficient regarding the relationship of age or physiological status to the medicine's effects. A persistent uncertainty across most indications is that long-term outcomes are not well characterized beyond the typical follow-up periods of the research. Overall, research provides context but not individual predictions.

Key Studies & References

  1. Antifibrinolytics (such as tranexamic acid) for treatment of heavy menstrual bleeding (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Relcon (FAQ)

Q: Is Relcon a new kind of medicine?

The active ingredient in Relcon is Tranexamic Acid, which is a synthetic substance that has been available and studied in medicine for several decades. The molecule was first patented in 1957, demonstrating that it has a long history of clinical use and regulatory review.


Q: Can Relcon be used for conditions other than the main ones listed?

Relcon is officially approved for specific medical indications, such as managing heavy menstrual bleeding and short-term use for certain bleeding prevention in patients. The use of the medicine is confined to the specific conditions outlined in the regulatory label.


Q: What are the possible long-term effects of taking Relcon?

Official labeling notes that the clinical studies conducted often have limited information on long-term outcomes for durations extending beyond the typical follow-up periods. The most serious risk documented in the safety profile is the potential for thromboembolic events (blood clots). The ongoing use of the medicine is based on a risk-benefit assessment made by a healthcare provider.


Q: How quickly should I expect to notice anything after starting Relcon?

Pharmacokinetic data describes the timeline of the medicine after administration. The substance reaches concentrations that help stabilize blood clots. The concentration remains in body tissues for approximately 17 hours, according to official data.


Q: Does Relcon have a generic version available?

Yes, the active ingredient in Relcon, which is Tranexamic Acid, is available in generic forms. These generic medicines are approved by regulatory agencies and are required to be therapeutically equivalent to the brand-name product.


Q: Can Relcon affect my ability to drive or operate machinery?

Regulatory documents note that Relcon may cause certain side effects, such as visual disturbances or dizziness. Official guidance includes a warning advising caution regarding driving or operating machinery until the patient knows how the medicine affects them.


Q: Is it normal to feel tired when you start taking Relcon?

Tiredness or fatigue is documented in patient information materials as a possible side effect that may occur when taking the medicine. These effects are classified along with other reported adverse reactions in official safety documentation.


Q: Does Relcon interact with common pain relievers like ibuprofen?

Official labeling does not explicitly list a specific interaction between Relcon and common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Official labeling recommends disclosing all concomitant use to a healthcare provider.


Q: Can Relcon be crushed or split if someone has trouble swallowing pills?

Official patient instructions specify that the tablets are designed to be swallowed whole. They are not intended to be split, chewed, or crushed, as this may alter how the medicine is absorbed or delivered.


Q: Do I need to take Relcon at the same time every day?

Official patient information contains a recommendation for taking the medicine at around the same times every day when a dose is due. This practice supports maintaining a consistent drug concentration in the body as established in the therapeutic plan.


Q: Are headaches a common side effect of Relcon?

Regulatory documents list headaches as a commonly reported side effect of the medicine. This is part of the established safety profile based on clinical trials and post-marketing surveillance.


Q: Is Relcon available over the counter?

In jurisdictions with major regulatory bodies like the U.S. and U.K., the medicine is classified as Prescription Only. This means Relcon is not available for purchase over the counter and requires a prescription from a licensed healthcare provider.


Q: Why does Relcon need to be prescribed by a doctor?

Relcon is classified as Prescription Only (Rx-only) because its use requires a professional assessment of the patient's risk factors. The classification is due to the need for professional oversight of patient risk factors and contraindications, particularly those related to the possibility of thromboembolic events.


Q: Are there different strengths or doses of Relcon?

The medicine is supplied in various dosage forms and strengths, including oral tablets and solutions for injection. These different preparations are used to suit varied clinical needs according to the official prescribing information.


Q: Is Relcon safe for older adults (seniors)?

Official research evidence indicates that data specifically for the older adult population is insufficient regarding the medicine's effects. Official documents note that the medicine's clearance is significantly reduced by impaired renal function, which is an important pharmacokinetic consideration for this population.


Q: Can women who are planning pregnancy use Relcon?

Official patient information advises women to inform their healthcare provider if they are planning to become pregnant before starting or continuing the use of Relcon. This disclosure is part of the established safety protocols for medicines used by women of reproductive potential.


Q: Is there a limit to how long someone can safely take Relcon?

For some approved uses, regulatory documentation defines a specific duration for treatment. For example, the oral tablet for heavy menstrual bleeding is typically limited to the 5 active bleeding days of the menstrual cycle. Other uses are generally defined as short-term treatments.


Q: How long does Relcon stay in my system after I stop taking it?

The substance has a terminal elimination half-life of approximately two hours, meaning its plasma concentration drops quickly. However, an effective concentration for stabilizing blood clots remains in various tissues for a longer duration, approximately 17 hours, according to pharmacokinetic data.


Q: Can I take Relcon if I have a history of heart problems?

Regulatory constraints emphasize the risk of thromboembolic events (blood clots). Eligibility for use requires a professional assessment to ensure an absence of risk factors for thrombosis.


Q: Do official documents mention Relcon being part of a combination therapy?

Official literature and clinical guidance mention the medicine being used in conjunction with other agents (e.g., oxytocin) to reduce bleeding in specific acute clinical scenarios, such as postpartum hemorrhage. This demonstrates its role as a component of specific treatment protocols.


Q: Is Relcon considered a Schedule [X] controlled substance?

The medicine is classified as a Prescription Only (Rx-only) drug and is not designated as a controlled substance in the U.S. by the Drug Enforcement Administration (DEA).


Q: Are there any post-marketing studies on Relcon?

Regulatory bodies require ongoing postmarketing reporting to monitor adverse events once a medicine is available to the public. This process ensures continuous review of the medicine's safety profile and collection of long-term data from a wider population.


Q: Is it possible for Relcon to interact with vitamins?

Patient information materials include a recommendation to inform a healthcare provider about all prescription and nonprescription medications, vitamins, and supplements being taken. This information disclosure is an established recommendation found in patient materials.


Q: What is the difference between the brand name and generic Relcon (if one existed)?

The active ingredient in both the brand-name product and its generic forms is Tranexamic Acid. Generic medicines are regulated to be therapeutically equivalent, meaning they work the same way in the body. Any differences are typically related to inactive ingredients, appearance, or cost.


Q: Are there specific criteria for who should be monitored while on Relcon?

Regulatory documents require professional oversight for certain conditions while the medicine is in use. These requirements include professional oversight for visual disturbances and retinal changes, and specific requirements are noted for patients with impaired renal (kidney) function.

How should Relcon be stored and disposed of?

Relcon (Tranexamic Acid) must be stored and handled according to the specific conditions defined in the regulatory labeling to maintain the product's stability.

Storage Requirements

Item Requirement (Official Regulatory Statement)
Storage Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted to 15 C to 30 C.
Protection Oral forms must be kept tightly closed to protect from moisture. The Injection solution must be protected from light and not stored above 30 C.
Stability If the Injection solution is diluted for infusion, the resulting mixture must be used within 24 hours (or 4 hours at room temperature, depending on the diluent) or discarded.
Child Safety The medicine must be stored out of the sight and reach of children.

Disposal Requirements

The disposal of Relcon must follow mandated environmental rules. The official labeling states that the product should not be disposed of via wastewater or household waste. Any unused or expired product must be discarded in accordance with local requirements, and users should consult a pharmacist for the proper procedure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Relcon found in:

A-Z Index: